471 related articles for article (PubMed ID: 30876658)
21. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.
Santema BT; Chan MMY; Tromp J; Dokter M; van der Wal HH; Emmens JE; Takens J; Samani NJ; Ng LL; Lang CC; van der Meer P; Ter Maaten JM; Damman K; Dickstein K; Cleland JG; Zannad F; Anker SD; Metra M; van der Harst P; de Boer RA; van Veldhuisen DJ; Rienstra M; Lam CSP; Voors AA
Clin Res Cardiol; 2020 Mar; 109(3):331-338. PubMed ID: 31263996
[TBL] [Abstract][Full Text] [Related]
22. Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?
Fudim M; Kelly JP; Jones AD; AbouEzzeddine OF; Ambrosy AP; Greene SJ; Reddy YNV; Anstrom KJ; Alhanti B; Lewis GD; Hernandez AF; Felker GM
Am Heart J; 2020 Feb; 220():97-107. PubMed ID: 31805424
[TBL] [Abstract][Full Text] [Related]
23. Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization.
Nikolova AP; Hitzeman TC; Baum R; Caldaruse AM; Agvanian S; Xie Y; Geft DR; Chang DH; Moriguchi JD; Hage A; Azarbal B; Czer LS; Kittleson MM; Patel JK; Wu AHB; Kobashigawa JA; Hamilton M; Hong T; Shaw RM
JAMA Cardiol; 2018 Dec; 3(12):1206-1210. PubMed ID: 30383171
[TBL] [Abstract][Full Text] [Related]
24. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
[TBL] [Abstract][Full Text] [Related]
25. Highest Obesity Category Associated With Largest Decrease in N-Terminal Pro-B-Type Natriuretic Peptide in Patients Hospitalized With Heart Failure With Preserved Ejection Fraction.
Vaishnav J; Chasler JE; Lee YJ; Ndumele CE; Hu JR; Schulman SP; Russell SD; Sharma K
J Am Heart Assoc; 2020 Aug; 9(15):e015738. PubMed ID: 32750299
[TBL] [Abstract][Full Text] [Related]
26. Comparison of clinical characteristics of patients with heart failure and preserved ejection fraction with atrial fibrillation versus sinus rhythm: Insights from the APOLLON registry.
Özlek B; Özlek E; Tekinalp M; Kahraman S; Zencirkiran Agus H; Başaran Ö; Kaya BC; Rencüzoğulları İ; Mert KU; Çakır O; Ösken A; Bekar L; Çelik Y; Çil C; Doğan V; Çelik O; Mert GÖ; Memiç Sancar K; Sevinç S; Biteker M
Turk Kardiyol Dern Ars; 2020 Apr; 48(3):234-245. PubMed ID: 32281959
[TBL] [Abstract][Full Text] [Related]
27. Association of Diastolic Dysfunction with N-terminal Pro-B-type Natriuretic Peptide Level in Heart Failure Patients with Preserved Ejection Fraction.
Islam MN; Chowdhury MS; Paul GK; Debnath RC; Shakil SS
Mymensingh Med J; 2019 Apr; 28(2):333-346. PubMed ID: 31086148
[TBL] [Abstract][Full Text] [Related]
28. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
[TBL] [Abstract][Full Text] [Related]
29. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
[TBL] [Abstract][Full Text] [Related]
30. Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction.
Kanagala P; Arnold JR; Cheng ASH; Singh A; Khan JN; Gulsin GS; Yang J; Zhao L; Gupta P; Squire IB; Ng LL; McCann GP
Int J Cardiovasc Imaging; 2020 Jan; 36(1):101-110. PubMed ID: 31401742
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
32. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.
McKelvie RS; Komajda M; McMurray J; Zile M; Ptaszynska A; Donovan M; Carson P; Massie BM;
J Card Fail; 2010 Feb; 16(2):128-34. PubMed ID: 20142024
[TBL] [Abstract][Full Text] [Related]
33. [Changes in NT-proBNP levels in patients with atrial fibrillation related to heart failure].
Pokorná V; Jurkovicová O; Kaluzay J; Stecová A; Pont'uch P
Vnitr Lek; 2010 Aug; 56(8):788-94. PubMed ID: 20845610
[TBL] [Abstract][Full Text] [Related]
34. Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial.
Borlaug BA; Anstrom KJ; Lewis GD; Shah SJ; Levine JA; Koepp GA; Givertz MM; Felker GM; LeWinter MM; Mann DL; Margulies KB; Smith AL; Tang WHW; Whellan DJ; Chen HH; Davila-Roman VG; McNulty S; Desvigne-Nickens P; Hernandez AF; Braunwald E; Redfield MM;
JAMA; 2018 Nov; 320(17):1764-1773. PubMed ID: 30398602
[TBL] [Abstract][Full Text] [Related]
35. N-terminal pro brain natriuretic peptide eliminates the prognostic effect of atrial fibrillation in patients with chronic heart failure.
Schnorbach J; Fröhlich H; Täger T; Corletto A; Katus HA; Frankenstein L
ESC Heart Fail; 2019 Aug; 6(4):640-648. PubMed ID: 31259484
[TBL] [Abstract][Full Text] [Related]
36. Effect of paced heart rate on quality of life and natriuretic peptides for stage B or C heart failure with preserved ejection fraction: A secondary analysis of the myPACE trial.
de la Espriella R; Wahlberg KJ; Infeld M; Palau P; Núñez E; Sanchis J; Meyer M; Núñez J
Eur J Heart Fail; 2024 Jan; 26(1):167-176. PubMed ID: 38124404
[TBL] [Abstract][Full Text] [Related]
37. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction.
Linssen GC; Rienstra M; Jaarsma T; Voors AA; van Gelder IC; Hillege HL; van Veldhuisen DJ
Eur J Heart Fail; 2011 Oct; 13(10):1111-20. PubMed ID: 21642293
[TBL] [Abstract][Full Text] [Related]
38. N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction - a randomized trial: The NICE study.
Pascual-Figal DA; Hernández-Vicente A; Pastor-Pérez F; Martínez-Sellés M; Solé-González E; Alvarez-García J; García-Pavía P; Varela-Román A; Sánchez PL; Delgado JF; Noguera-Velasco JA; Bayes-Genis A;
Eur J Heart Fail; 2024 Apr; 26(4):776-784. PubMed ID: 38606524
[TBL] [Abstract][Full Text] [Related]
39. Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF).
Sobue Y; Watanabe E; Lip GYH; Koshikawa M; Ichikawa T; Kawai M; Harada M; Inamasu J; Ozaki Y
Heart Vessels; 2018 Apr; 33(4):403-412. PubMed ID: 29067492
[TBL] [Abstract][Full Text] [Related]
40. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.
Zakeri R; Borlaug BA; McNulty SE; Mohammed SF; Lewis GD; Semigran MJ; Deswal A; LeWinter M; Hernandez AF; Braunwald E; Redfield MM
Circ Heart Fail; 2014 Jan; 7(1):123-30. PubMed ID: 24162898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
